Top

Published in:

Open Access 01-12-2022 | Respiratory Microbiota | Research

Poria cocos polysaccharides exert prebiotic function to attenuate the adverse effects and improve the therapeutic outcome of 5-FU in Apc^Min/+ mice

Authors: Lin Yin, Guoxin Huang, Imran Khan, Lu Su, Wenrui Xia, Betty Yuen Kwan Law, Vincent Kam Wai Wong, Qiang Wu, Jingyi Wang, Wai Kit Leong, W. L. Wendy Hsiao

Published in: Chinese Medicine | Issue 1/2022

Abstract

Background

As a first-line chemotherapeutic agent, 5-fluorouracil (5-FU) exhibits many side effects, weakening its efficacy in cancer treatment. In this study, we hypothesize that Poria cocos polysaccharides (PCP), a traditional Chinese herbal medicine with various bioactivities and prebiotic effects, might improve the therapeutic effect of 5-FU by restoring the homeostasis of the gut microenvironment and the commensal gut microflora.

Methods

Apc^Min/+ mice were employed to evaluate the anti-cancer effect of 5-FU in conjunction with PCP treatment. Body weight and food consumption were monitored weekly. Polyp count was used to assess the anti-cancer effect of PCP and 5-FU. Expressions of mucosal cytokines and gut epithelial junction molecules were measured using qRT-PCR. 16S rRNA gene sequencing of fecal DNAs was used to evaluate the compositional changes of gut microbiota (GM). Transplantation of Lactobacillus johnsonii and Bifidobacterium animalis were performed to verify the prebiotic effects of PCP in improving the efficacy of 5-FU.

Results

The results showed that PCP treatment alleviated the weight loss caused by 5-FU treatment and reduced the polyp burden in Apc^Min/+ mice. Additionally, PCP treatment eased the cytotoxic effects of 5-FU by reducing the expressions of pro-inflammatory cytokines, increasing the anti-inflammatory cytokines; and significantly improving the gut barriers by enhancing the tight junction proteins and associated adhesion molecules. Furthermore, 16S rRNA gene sequencing data showed that PCP alone or with 5-FU could stimulate the growth of probiotic bacteria (Bacteroides acidifaciens, Bacteroides intestinihominis, Butyricicoccus pullicaecorum, and the genera Lactobacillus, Bifidobacterium, Eubacterium). At the same time, it inhibited the growth of potential pathogens (e.g., Alistipes finegoldii, Alistipes massiliensis, Alistipes putredinis., Citrobacter spp., Desulfovibrio spp., and Desulfovibrio desulfuricans). Moreover, the results showed that transplantation of L.johnsonii and B.animalis effectively reduced the polyp burden in Apc^Min/+ mice being treated with 5-FU.

Conclusion

Our study showed that PCP could effectively improve the anti-cancer effect of 5-FU by attenuating its side effects, modulating intestinal inflammation, improving the gut epithelial barrier, and modulating the gut microbiota of Apc^Min/+ mice.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Ghiringhelli F, Apetoh L. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives. Biomed J. 2015;38(2):111–6. https://doi.org/10.4103/2319-4170.130923.CrossRefPubMed

Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. https://doi.org/10.1038/nrc1074.CrossRefPubMed

Hamouda N, Sano T, Oikawa Y, Ozaki T, Shimakawa M, Matsumoto K, Amagase K, Higuchi K, Kato S. Apoptosis, dysbiosis and expression of inflammatory cytokines are sequential events in the development of 5-fluorouracil-induced intestinal muco-sitis in mice. Basic Clin Pharmacol Toxicol. 2017;121(3):159–68. https://doi.org/10.1111/bcpt.12793.CrossRefPubMed

Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(S9):1995–2025. https://doi.org/10.1002/cncr.20162.CrossRefPubMed

Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136(1):65–80. https://doi.org/10.1053/j.gastro.2008.10.080.CrossRefPubMed

Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005;3(5):431–8. https://doi.org/10.1038/nrmicro1152.CrossRefPubMed

Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut mi-crobiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14(6):356–65. https://doi.org/10.1038/nrgastro.2017.20.CrossRefPubMed

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–6. https://doi.org/10.1126/science.1240537.CrossRefPubMedPubMedCentral

10.

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–70. https://doi.org/10.1126/science.1240527.CrossRefPubMedPubMedCentral

11.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84. https://doi.org/10.1126/science.aad1329.CrossRefPubMedPubMedCentral

12.

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(6264):1084–9. https://doi.org/10.1126/science.aac4255.CrossRefPubMedPubMedCentral

13.

Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and cl-inical applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690–704. https://doi.org/10.1038/s41575-019-0209-8.CrossRefPubMed

14.

Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu Rev Microbiol. 2016;70:395–411. https://doi.org/10.1146/annurev-micro-102215-095513.CrossRefPubMedPubMedCentral

15.

Wu J, Gan Y, Li M, Chen L, Liang J, Zhuo J, Luo H, Xu N, Wu X, Wu Q. Patcho-uli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota. Biomed Pharmacother. 2020;124: 109883. https://doi.org/10.1016/j.biopha.2020.109883.CrossRefPubMed

16.

Li H-L, Lu L, Wang X-S, Qin L-Y, Wang P, Qiu S-P, Wu H, Huang F, Zhang B-B, Shi H-L. Alteration of gut microbiota and inflammatory cytokine/chemokine profil-es in 5-fluorouracil induced intestinal mucositis. Front Cell Infect Microbiol. 2017;7:455. https://doi.org/10.3389/fcimb.2017.00455.CrossRefPubMedPubMedCentral

17.

Yuan L, Zhang S, Li H, Yang F, Mushtaq N, Ullah S, Shi Y, An C, Xu J. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. Biomed Pharmacother. 2018;108:184–93. https://doi.org/10.1016/j.biopha.2018.08.165.CrossRefPubMed

18.

Sougiannis A, VanderVeen B, Enos R, Velazquez K, Bader J, Carson M, Chatzist-amou I, Walla M, Pena M, Kubinak J. Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. Brain, behavior, and im-munity. 2019;80:44–55. https://doi.org/10.1016/j.bbi.2019.02.020.CrossRef

19.

Justino PF, Melo LF, Nogueira AF, Costa JV, Silva LM, Santos CM, Mendes WO, Costa MR, Franco AX, Lima AA. Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. Br J Nutr. 2014;111(9):1611–21. https://doi.org/10.1017/S0007114513004248.CrossRefPubMed

20.

Wu T, Munro AJ, Guanjian L, Liu GJ. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005. https://doi.org/10.1002/14651858.CD004540.pub2.CrossRefPubMedPubMedCentral

21.

Chen K-J, Huang Y-L, Kuo L-M, Chen Y-T, Hung C-F, Hsieh P-W. Protective role of casuarinin from Melastoma malabathricum against a mouse model of 5-fluorouracil–induced intestinal mucositis: Impact on inflammation and gut microbiota dys-biosis. Phytomedicine. 2022;101: 154092. https://doi.org/10.1016/j.phymed.2022.154092.CrossRefPubMed

22.

Huang G, Khan I, Li X, Chen L, Leong W, Ho LT, Hsiao WLW. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017;7(1):12552. https://doi.org/10.1038/s41598-017-12644-5.CrossRefPubMedPubMedCentral

23.

Khan I, Huang G, Li X, Leong W, Xia W, Hsiao WLW. Mushroom polysaccharides from Ganoderma lucidum and Poria cocos reveal prebiotic functions. J Funct Foods. 2018;41:191–201. https://doi.org/10.1016/j.jff.2017.12.046.CrossRef

24.

Khan I, Huang G, Li X, Liao W, Leong WK, Xia W, Bian X, Wu J, Hsiao WLW. Mushroom polysaccharides and jiaogulan saponins exert cancer preventive effects by shaping the gut microbiota and microenvironment in ApcMin/+ mice. Pharmacolo-gical Res. 2019;148: 104448. https://doi.org/10.1016/j.phrs.2019.104448.CrossRef

25.

Xia W, Li X, Khan I, Yin L, Su L, Leong WK, Bian X, Su J, Hsiao W, Huang G. Lycium Berry polysaccharides strengthen gut microenvironment and modulate gut microbiota of the mice. Evid Based Complement Alternat Med. 2020. https://doi.org/10.1155/2020/8097021.CrossRefPubMedPubMedCentral

26.

Sun S-S, Wang K, Ma K, Bao L, Liu H-W. An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia, hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota. Chin J Nat Med. 2019;17(1):3–14. https://doi.org/10.1016/s1875-5364(19)30003-2.CrossRefPubMed

27.

Jiang Y, Fan L. The effect of Poria cocos ethanol extract on the intestinal barrier function and intestinal microbiota in mice with breast cancer. J Ethnopharmacol. 2021;266: 113456. https://doi.org/10.1016/j.jep.2020.113456.CrossRefPubMed

28.

Wang N, Liu D, Guo J, Sun Y, Guo T, Zhu X. Molecular mechanism of Poria cocos combined with oxaliplatin on the inhibition of epithelial-mesenchymal transition in gastric cancer cells. Biomed Pharmacother. 2018;102:865–73. https://doi.org/10.1016/j.biopha.2018.03.134.CrossRefPubMed

29.

Wang J, Zheng D, Huang F, Zhao A, Kuang J, Ren Z, Chen T, Lei J, Lin J, Wang X, Jia W, Xie G, Zheng X. Theabrownin and Poria cocos polysaccharide improve lipid metabolism via modulation of bile acid and fatty acid metabolism. Front Pharmacol. 2022;13: 875549. https://doi.org/10.3389/fphar.2022.875549.CrossRefPubMedPubMedCentral

30.

Lai Y, Yu H, Deng H, Fang Q, Lei H, Liu L, Wu N, Guo X, Song C. Three main metabolites from Wolfiporia cocos (F. A. Wolf) Ryvarden & Gilb regulate the gut microbiota in mice: a comparative study using microbiome-metabolomics. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.911140.CrossRefPubMedPubMedCentral

31.

Sun S, Wang K, Sun L, Cheng B, Qiao S, Dai H, Shi W, Ma J, Liu H. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis. Gut Microbes. 2020;12(1):1830693. https://doi.org/10.1080/19490976.2020.1830693.CrossRefPubMedPubMedCentral

32.

Chen L, Brar MS, Leung FC, Hsiao WW. Triterpenoid herbal saponins enhance beneficial bacteria, decrease sulfate-reducing bacteria, modulate inflammatory intestinal microenvironment and exert cancer preventive effects in ApcMin/+ mice. Oncotarget. 2016;7(21):31226. https://doi.org/10.1080/19490976.2020.CrossRefPubMedPubMedCentral

33.

Dowd SE, Sun Y, Wolcott RD, Domingo A, Carroll JA. Bacterial tag–encoded FLX amplicon pyrosequencing (bTEFAP) for microbiome studies: bacterial diversity in the ileum of newly weaned Salmonella-infected pigs. Foodborne Pathog Dis. 2008;5(4):459–72. https://doi.org/10.1089/fpd.2008.0107.CrossRefPubMed

34.

Li X, Khan I, Xia W, Huang G, Liu L, Law BYK, Yin L, Liao W, Leong W, Han R. Icariin enhances youth-like features by attenuating the declined gut microbiota in the aged mice. Pharmacol Res. 2021;168: 105587. https://doi.org/10.1016/j.phrs.2021.105587.CrossRefPubMed

35.

Liao W, Khan I, Huang G, Chen S, Liu L, Leong WK, Li XA, Wu J, Wendy Hsiao WL. Bifidobacterium animalis: the missing link for the cancer-preventive effect of Gynostemma pentaphyllum. Gut Microbes. 2021;13(1):1847629. https://doi.org/10.1080/19490976.2020.1847629.CrossRefPubMed

36.

Puppa MJ, White JP, Sato S, Cairns M, Baynes JW, Carson JA. Gut barrier dysfunction in the ApcMin/+ mouse model of colon cancer cachexia. Biochim Biophys Acta. 2011;1812(12):1601–6. https://doi.org/10.1016/j.bbadis.2011.08.010.CrossRefPubMedPubMedCentral

37.

Allen-Vercoe E, Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC? Immunol Lett. 2014;162(2):54–61. https://doi.org/10.1016/j.imlet.2014.05.014.CrossRefPubMedPubMedCentral

38.

Loh C-Y, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118. https://doi.org/10.3390/cells8101118.CrossRefPubMedCentral

39.

Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Investig. 2012;122(3):787–95. https://doi.org/10.1172/JCI59643.CrossRefPubMedPubMedCentral

40.

Perillo F, Amoroso C, Strati F, Giuffrè MR, Díaz-Basabe A, Lattanzi G, Facciotti F. Gut microbiota manipulation as a tool for colorectal cancer management: recent advances in its use for therapeutic purposes. Int J Mol Sci. 2020;21(15):5389. https://doi.org/10.3390/ijms21155389.CrossRefPubMedCentral

41.

Osman MA, Neoh H-M, Ab Mutalib N-S, Chin S-F, Mazlan L, Raja Ali RA, Zakaria AD, Ngiu CS, Ang MY, Jamal R. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci Rep. 2021;11(1):1–12. https://doi.org/10.1038/s41598-021-82465-0.CrossRef

42.

Selvanantham T, Lin Q, Guo CX, Surendra A, Fieve S, Escalante NK, Guttman DS, Streutker CJ, Robertson SJ, Philpott DJ. NKT cell–deficient mice harbor an altered microbiota that fuels intestinal inflammation during chemically induced colitis. J Immunol. 2016;197(11):4464–72. https://doi.org/10.4049/jimmunol.1601410.CrossRefPubMed

43.

Shah AM, Ma J, Wang Z, Hu R, Wang X, Peng Q, Amevor FK, Goswami N. Production of hydrogen sulfide by fermentation in rumen and its impact on health and production of animals. Processes. 2020;8(9):1169. https://doi.org/10.3390/pr8091169.CrossRef

44.

Attene-Ramos MS, Nava GM, Muellner MG, Wagner ED, Plewa MJ, Gaskins HR. DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. Environ Mol Mutagen. 2010;51(4):304–14. https://doi.org/10.1002/em.20546.CrossRefPubMed

45.

Hullar MA, Burnett-Hartman AN, Lampe JW. Gut microbes, diet, and cancer. In: Zappia Vincenzo, Panico Salvatore, Russo Gian Luigi, Budillon Alfredo, Ragione Fulvio Della, editors. Advances in nutrition and cancer. Heidelberg: Springer; 2014.

46.

Dekker JP, Frank KM. Salmonella, Shigella, and yersinia. Clin Lab Med. 2015;35(2):225–46. https://doi.org/10.1016/j.cll.2015.02.002.CrossRefPubMedPubMedCentral

47.

Parker BJ, Wearsch PA, Veloo A, Rodriguez-Palacios A. The genus Alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906. https://doi.org/10.3389/fimmu.2020.00906.CrossRefPubMedPubMedCentral

48.

Gibson DL, Ma C, Rosenberger CM, Bergstrom KS, Valdez Y, Huang JT, Khan MA, Vallance BA. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol. 2008;10(2):388–403. https://doi.org/10.1111/j.1462-5822.2007.01052.x.CrossRefPubMed

49.

Luperchio SA, Schauer DB. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect. 2001;3(4):333–40. https://doi.org/10.1016/S1286-4579(01)01387-9.CrossRefPubMed

50.

Den Besten G, Van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325–40. https://doi.org/10.1194/jlr.R036012.CrossRef

51.

Chen H, Zhang F, Li R, Liu Y, Wang X, Zhang X, Xu C, Li Y, Guo Y, Yao Q. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota. Biomed Pharmacother. 2020;124: 109829. https://doi.org/10.1016/j.biopha.2020.109829.CrossRefPubMed

52.

Wang C, Yang S, Gao L, Wang L, Cao L. Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. Food Funct. 2018;9(5):2695–704. https://doi.org/10.1039/c7fo01886j.CrossRefPubMed

53.

Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y, Jiang X. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res. 2021;165: 105420. https://doi.org/10.1016/j.phrs.2021.105420.CrossRefPubMed

54.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200. https://doi.org/10.1080/19490976.2015.1134082.CrossRefPubMedPubMedCentral

55.

Parada Venegas D, De la Fuente MK, Landskron G, Gonzalez MJ, Quera R, Dijks-tra G, Harmsen HJM, Faber KN, Hermoso MA. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019;10:277. https://doi.org/10.3389/fimmu.2019.00277.CrossRefPubMedPubMedCentral

56.

Fonseca W, Lucey K, Jang S, Fujimura KE, Rasky A, Ting HA, Petersen J, Johnson CC, Boushey HA, Zoratti E, Ownby DR, Levine AM, Bobbit KR, Lynch SV, Lukacs NW. Lactobacillus johnsonii supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation. Mucosal Immunol. 2017;10(6):1569–80. https://doi.org/10.1038/mi.2017.13.CrossRefPubMedPubMedCentral

57.

Yamamoto ML, Maier I, Dang AT, Berry D, Liu J, Ruegger PM, Yang JI, Soto PA, Presley LL, Reliene R, Westbrook AM, Wei B, Loy A, Chang C, Braun J, Borneman J, Schiestl RH. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 2013;73(14):4222–32. https://doi.org/10.1158/0008-5472.CAN-13-0022.CrossRefPubMedPubMedCentral

Title: Poria cocos polysaccharides exert prebiotic function to attenuate the adverse effects and improve the therapeutic outcome of 5-FU in ApcMin/+ mice
Authors: Lin Yin
Guoxin Huang
Imran Khan
Lu Su
Wenrui Xia
Betty Yuen Kwan Law
Vincent Kam Wai Wong
Qiang Wu
Jingyi Wang
Wai Kit Leong
W. L. Wendy Hsiao
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Respiratory Microbiota
Cytokines
Published in: Chinese Medicine / Issue 1/2022
Electronic ISSN: 1749-8546
DOI: https://doi.org/10.1186/s13020-022-00667-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Poria cocos polysaccharides exert prebiotic function to attenuate the adverse effects and improve the therapeutic outcome of 5-FU in Apc^Min/+ mice

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Combination of pseudoephedrine and emodin ameliorates LPS-induced acute lung injury by regulating macrophage M1/M2 polarization through the VIP/cAMP/PKA pathway

Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review

Effects of acupuncture at acupoints with lower versus higher pain threshold for knee osteoarthritis: a multicenter randomized controlled trial

Lipidomics combined with transcriptomic and mass spectrometry imaging analysis of the Asiatic toad (Bufo gargarizans) during metamorphosis and bufadienolide accumulation

An integrated study of Violae Herba (Viola philippica) and five adulterants by morphology, chemical compositions and chloroplast genomes: insights into its certified plant origin

Chemometrics integrated with in silico pharmacology to reveal antioxidative and anti-inflammatory markers of dandelion for its quality control